AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims

Claims 1-68 (canceled).

Claim 69 (currently amended): A method for inducing tissue formation at a locus accessible to at least one progenitor cell of a mammal, wherein the tissue is selected from the group consisting of bone, cartilage, tendon/ligament and neural tissue, comprising the step of implanting a morphogenic device, whereby the morphogenic device induces tissue formation from the progenitor cell in the mammal, the morphogenic device comprising:

a) an implantable biocompatible carrier,

b) a morphogenic protein comprising a polypeptide selected from the group consisting of ~~BMP-4,~~ BMP-5, BMP-6, BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, Dpp, Vg-1, COP-5 and COP-7 disposed in the carrier, the morphogenic protein

capable of inducing tissue formation when accessible to the progenitor cell, and

c) a morphogenic protein stimulatory factor (MPSF) selected from the group consisting of IGF-I, hydrocortisone, insulin and parathyroid hormone, wherein said MPSF is disposed in the carrier, and wherein said MPSF is at a concentration effective to synergistically stimulate the ability of the morphogenic protein to induce tissue formation from the progenitor cell.

Claim 70 (withdrawn): The method according to claim 69, wherein the locus is a jaw bone for use in periodontal or dental reconstructive procedures.

Claim 71 (previously presented): The method according to claim 69, wherein the locus is a bone defect selected from the group consisting of a fracture, a non-union fracture, a fusion and a bony void.

Claim 72 (withdrawn): The method according to claim 69, wherein the locus is a joint for use in cartilage and soft tissue repair.

Claim 73 (withdrawn): The method according to claim 69, wherein the locus is nervous system-associated tissue for use in neural regeneration and repair.

Claims 74-101 (canceled).

Claim 102 (previously presented): The method according to claim 69, wherein the carrier comprises heparin or a salt thereof.

Claims 103-105 (canceled).

Claim 106 (previously presented): The method according to claim 69, wherein the morphogenic protein comprises a pair of subunits disulfide bonded to produce a dimeric species.

Claim 107 (canceled).

Claim 108 (previously presented): The method according to claim 69, wherein the morphogenic protein is capable of inducing the progenitor cell to form endochondral or intramembranous bone.

Claim 109 (previously presented): The method according to claim 69, wherein the morphogenic protein is capable of inducing the progenitor cell to form cartilage.

Claim 110 (previously presented): The method according to claim 69, wherein the morphogenic protein is capable of inducing the progenitor cell to form tendon/ligament tissue or neural tissue.

Claim 111 (canceled).

Claim 112 (currently amended): The method according to claim 69, wherein the morphogenic protein comprises a polypeptide selected from the group consisting of BMP-7 (OP-1)~~, BMP-4~~ and BMP-6.

Claim 113 (previously presented): The method according to claim 69, wherein the morphogenic protein comprises BMP-7 (OP-1).

Claim 114 (previously presented): The method according to claim 106, wherein the dimeric species is a homo- or hetero-dimer comprising at least one BMP-7 (OP-1) subunit.

Claim 115 (previously presented): The method according to claim 69, wherein the morphogenic protein stimulatory factor is IGF-I.

Claim 116 (previously presented): The method according to claim 69, wherein the morphogenic protein is present in a pharmaceutical composition at a concentration of at least about 1 ng/ml, and the morphogenic protein stimulatory factor is present in the pharmaceutical composition at a concentration of at least about 0.01 ng/ml.

Claim 117 (previously presented): The method according to claim 69, wherein the morphogenic protein is BMP-7 (OP-1) and is present in a pharmaceutical composition at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor is IGF-I and is present in the pharmaceutical composition at a concentration of from about 0.1 ng/ml to about 50 ng/ml.

Claim 118 (previously amended): The method according to claim 69, wherein the morphogenic protein is BMP-7 (OP-1) and is present in a pharmaceutical composition at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein

stimulatory factor is hydrocortisone and is present in the pharmaceutical composition at a concentration of from about 0.05 nM to about 5.0 nM.

Claim 119 (withdrawn): The method according to claim 118, wherein BMP-7 (OP-1) is about 200 ng/ml and hydrocortisone is about 0.5 - 5.0 nM.

Claim 120 (previously amended): The method according to claim 69, wherein the morphogenic protein is BMP-7 (OP-1) and is present in a pharmaceutical composition at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor is insulin and is present in the pharmaceutical composition at a concentration of from about 0.01 nM to about 1000 nM.

Claim 121 (previously amended): The method according to claim 69, wherein the morphogenic protein is BMP-7 (OP-1) and is present in a pharmaceutical composition at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor is parathyroid hormone and is present in the pharmaceutical composition at a concentration of from about 10 nM to about 1000 nM.

Claim 122 (withdrawn): The method according to claim 121, wherein BMP-7 (OP-1) is about 200 ng/ml and parathyroid hormone is about 25-200 nM.